Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Leiomyosarcoma × dinutuximab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neuroblastoma 13 Rhabdomyosarcoma, Embryonal 1 Rhabdomyosarcoma, Alveolar 1 Osteosarcoma 1 Neoplasms 1 Neoplasm, Residual 1 Leiomyosarcoma 1 Ganglioneuroblastoma 1 Bone Neoplasms 1

Interventions

Gemcitabine 14 Docetaxel 8 Doxorubicin 7 Radiotherapy 6 Trabectedin 5 pazopanib 4 Sunitinib 3 Nivolumab 3 Dacarbazine 3 liposomal doxorubicin 2 eribulin 2 avelumab 2 Specimen Handling 2 Radiation Dose Hypofractionation 2 Letrozole 2 Ifosfamide 2 Bevacizumab 2 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2 tremelimumab 1 temsirolimus 1 sotigalimab 1 selinexor 1 sargramostim 1 ribociclib 1 regorafenib 1 pembrolizumab 1 pegfilgrastim 1 niraparib 1 lenvatinib 1 lentiviral minigene vaccine of COVID-19 coronavirus 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05080790 2025-08-17

DiTuSarc

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2 Completed

Leiomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡